Autoimmune Diseases — Comparative Analysis of the Th17 Cellular Response in Active and Inactive Pemphigus Vulgaris Patients
Citation(s)
Agarwal V, Mittal SK, Misra R Expression of multidrug resistance-1 protein correlates with disease activity rather than the refractoriness to methotrexate therapy in rheumatoid arthritis. Clin Rheumatol. 2009 Apr;28(4):427-33. doi: 10.1007/s10067-008-1071-1. Epub 2009 Jan 10.
Arakawa M, Dainichi T, Yasumoto S, Hashimoto T Lesional Th17 cells in pemphigus vulgaris and pemphigus foliaceus. J Dermatol Sci. 2009 Mar;53(3):228-31. doi: 10.1016/j.jdermsci.2008.09.008. Epub 2008 Nov 5.
Asothai R, Anand V, Das D, Antil PS, Khandpur S, Sharma VK, Sharma A Distinctive Treg associated CCR4-CCL22 expression profile with altered frequency of Th17/Treg cell in the immunopathogenesis of Pemphigus Vulgaris. Immunobiology. 2015 Oct;220(10):1129-35. doi: 10.1016/j.imbio.2015.06.008. Epub 2015 Jun 17.
Bauer B, Hartz AM, Miller DS Tumor necrosis factor alpha and endothelin-1 increase P-glycoprotein expression and transport activity at the blood-brain barrier. Mol Pharmacol. 2007 Mar;71(3):667-75. Epub 2006 Nov 28.
Borst P, Elferink RO Mammalian ABC transporters in health and disease. Annu Rev Biochem. 2002;71:537-92. Epub 2001 Nov 9. Review.
Bystryn JC, Steinman NM The adjuvant therapy of pemphigus. An update. Arch Dermatol. 1996 Feb;132(2):203-12. Review.
Giordano CN, Sinha AA Cytokine networks in Pemphigus vulgaris: An integrated viewpoint. Autoimmunity. 2012 Sep;45(6):427-39. doi: 10.3109/08916934.2012.697593. Epub 2012 Jul 13. Review.
Gottesman MM, Pastan I Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem. 1993;62:385-427. Review.
Grogan JL, Ouyang W A role for Th17 cells in the regulation of tertiary lymphoid follicles. Eur J Immunol. 2012 Sep;42(9):2255-62. doi: 10.1002/eji.201242656. Review.
Hartz AM, Bauer B, Fricker G, Miller DS Rapid modulation of P-glycoprotein-mediated transport at the blood-brain barrier by tumor necrosis factor-alpha and lipopolysaccharide. Mol Pharmacol. 2006 Feb;69(2):462-70. Epub 2005 Nov 8.
Heaphy MR, Albrecht J, Werth VP Dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris. Arch Dermatol. 2005 Jun;141(6):699-702.
Herbst A, Bystryn JC Patterns of remission in pemphigus vulgaris. J Am Acad Dermatol. 2000 Mar;42(3):422-7.
Higgins CF ABC transporters: from microorganisms to man. Annu Rev Cell Biol. 1992;8:67-113. Review.
Horio M, Gottesman MM, Pastan I ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells. Proc Natl Acad Sci U S A. 1988 May;85(10):3580-4.
McClean S, Hill BT Evidence of post-translational regulation of P-glycoprotein associated with the expression of a distinctive multiple drug-resistant phenotype in Chinese hamster ovary cells. Eur J Cancer. 1993;29A(16):2243-8.
Pfütze M, Niedermeier A, Hertl M, Eming R Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus. Eur J Dermatol. 2007 Jan-Feb;17(1):4-11. Epub 2007 Feb 27. Review.
Pisanti S, Sharav Y, Kaufman E, Posner LN Pemphigus vulgaris: incidence in Jews of different ethnic groups, according to age, sex, and initial lesion. Oral Surg Oral Med Oral Pathol. 1974 Sep;38(3):382-7.
Richaud-Patin Y, Vega-Boada F, Vidaller A, Llorente L Multidrug resistance-1 (MDR-1) in autoimmune disorders IV. P-glycoprotein overfunction in lymphocytes from myasthenia gravis patients. Biomed Pharmacother. 2004 Jun;58(5):320-4.
Ruiz-Soto R, Richaud-Patin Y, López-Karpovitch X, Llorente L Multidrug resistance-1 (MDR-1) in autoimmune disorders III: increased P-glycoprotein activity in lymphocytes from immune thrombocytopenic purpura patients. Exp Hematol. 2003 Jun;31(6):483-7.
Steinman L A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med. 2007 Feb;13(2):139-45. Review. Erratum in: Nat Med. 2007 Mar;13(3):385.
Tsujimura S, Saito K, Nawata M, Nakayamada S, Tanaka Y Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis. Ann Rheum Dis. 2008 Mar;67(3):380-8. Epub 2007 Jul 27.
Tsujimura S, Tanaka Y Treatment strategy based on targeting P-glycoprotein on peripheral lymphocytes in patients with systemic autoimmune disease. Clin Exp Nephrol. 2012 Feb;16(1):102-8. doi: 10.1007/s10157-011-0520-3. Epub 2011 Aug 17. Review.
Wolking S, Schaeffeler E, Lerche H, Schwab M, Nies AT Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature. Clin Pharmacokinet. 2015 Jul;54(7):709-35. doi: 10.1007/s40262-015-0267-1. Review.
Xue J, Su W, Chen Z, Ke Y, Du X, Zhou Q Overexpression of interleukin-23 and interleukin-17 in the lesion of pemphigus vulgaris: a preliminary study. Mediators Inflamm. 2014;2014:463928. doi: 10.1155/2014/463928. Epub 2014 May 11.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.